FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318994932> ?p ?o ?g. }

• W2318994932 abstract "Event Abstract Back to Event Circulating Fibroblast Growth Factor-23 (FGF-23) following vitamin D supplementation in vitamin D insufficiency R Inaoui1*, WD Fraser2, I Fogelman1 and G Hampson1 1 Guy's Hospital, Osteoporosis Clinic, Rheumatology, United Kingdom 2 Royal Liverpool Hospital, Department of Clinical Chemistry, United Kingdom 1,25 dihydroxy vitamin D up-regulates Fibroblast Growth Factor -23 (FGF-23). Both are implicated in a feedback loop, as increases in FGF-23 inhibit 1, 25 dihydroxy vitamin D synthesis. High dose vitamin D supplements are frequently given to patients with low 25(OH) vitaminD who are at high fracture risk. We investigated the effect of high dose vitamin D on circulating FGF-23 concentrations and the interaction between FGF-23 and 1, 25 dihydroxy vitaminD in patients with vitamin D deficiency /insufficiency. Thirty one subjects (11M aged (mean [SD]) 56.6 [19.3] and 20 F aged 62.7 [15.3] years were studied. They were administered an intra-muscular injection of 300,000 I.U of Ergocalciferol (D2) and prescribed daily supplements of calcium (1.2 g) and 800 I.U colecalciferol (D3). Blood samples were obtained at baseline, 1, 2 and 3 months for measurement of serum calcium, phosphate, PTH, 25 (OH) vitamin D and FGF-23. 1,25dihydroxyvitamin D was measured at baseline and 3 months. Serum 25 (OH) vitamin D increased significantly (baseline mean [SD] 33.5 [14.9], 50.5 [21.6] nmol/L at 3 months (p < 0.05). PTH decreased from baseline, but not significantly (baseline: 64[60], 3 months: 50[28.5] ng/L). There was no significant difference in serum phosphate. FGF-23 concentrations increased significantly (baseline: 85.3[44.1], 1 month : 111[58], 2 month : 99.6 [62], 3 month: 108[59] RU/ml (p <0.05). A positive correlation was seen between FGF-23 and serum phosphate at 3 months (r= 0.44, p= 0.02). 1, 25 dihydroxyvitamin D increased in 18 patients (Group A : baseline 107 [39] , 3 month 134[34.5] pmol/L) and decreased in 13 patients (Group B : baseline 158.6 [40] , 3 months 123 [37] pmol/L p<0.05). Baseline 1, 25 dihydroxyvitamin D was significantly higher in Group B compared to Group A (p<0.001). There was no significant difference in PTH. A larger increase in FGF-23 was seen in Group B (Group B mean [SEM] % change from baseline; 1 month: 90[47], 2 month: 84[44], 3 month: 45[16], Group A; 1 month: 36[12.5], 2 month: 14 [10], 3 month: 29 [15] p=0.039). These data suggest that FGF-23 is a counter-regulatory hormone for 1, 25 dihydroxy vitamin D production. Keywords: Bones, Bone Research Conference: 2011 joint meeting of the Bone Research Society & the British Orthopaedic Research Society, Cambridge, United Kingdom, 27 Jun - 29 Jun, 2011. Presentation Type: Oral Topic: Abstracts Citation: Inaoui R, Fraser W, Fogelman I and Hampson G (2011). Circulating Fibroblast Growth Factor-23 (FGF-23) following vitamin D supplementation in vitamin D insufficiency. Front. Endocrinol. Conference Abstract: 2011 joint meeting of the Bone Research Society & the British Orthopaedic Research Society. doi: 10.3389/conf.fendo.2011.02.00029 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 30 Sep 2011; Published Online: 30 Sep 2011. * Correspondence: Dr. R Inaoui, Guy's Hospital, Osteoporosis Clinic, Rheumatology, London, United Kingdom, rachidainaoui@wanadoo.fr Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers R Inaoui WD Fraser I Fogelman G Hampson Google R Inaoui WD Fraser I Fogelman G Hampson Google Scholar R Inaoui WD Fraser I Fogelman G Hampson PubMed R Inaoui WD Fraser I Fogelman G Hampson Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page." @default.
• W2318994932 created "2016-06-24" @default.
• W2318994932 creator A5000844351 @default.
• W2318994932 date "2011-01-01" @default.
• W2318994932 modified "2023-10-16" @default.
• W2318994932 title "Circulating Fibroblast Growth Factor-23 (FGF-23) following vitamin D supplementation in vitamin D insufficiency" @default.
• W2318994932 doi "https://doi.org/10.3389/conf.fendo.2011.02.00029" @default.
• W2318994932 hasPublicationYear "2011" @default.
• W2318994932 type Work @default.
• W2318994932 sameAs 2318994932 @default.
• W2318994932 citedByCount "0" @default.
• W2318994932 crossrefType "journal-article" @default.
• W2318994932 hasAuthorship W2318994932A5000844351 @default.
• W2318994932 hasBestOaLocation W23189949321 @default.
• W2318994932 hasConcept C114276007 @default.
• W2318994932 hasConcept C124490489 @default.
• W2318994932 hasConcept C126322002 @default.
• W2318994932 hasConcept C134018914 @default.
• W2318994932 hasConcept C170493617 @default.
• W2318994932 hasConcept C2776541429 @default.
• W2318994932 hasConcept C2776940978 @default.
• W2318994932 hasConcept C2777621572 @default.
• W2318994932 hasConcept C2779740938 @default.
• W2318994932 hasConcept C2780106736 @default.
• W2318994932 hasConcept C2781208988 @default.
• W2318994932 hasConcept C519063684 @default.
• W2318994932 hasConcept C71924100 @default.
• W2318994932 hasConcept C74373430 @default.
• W2318994932 hasConceptScore W2318994932C114276007 @default.
• W2318994932 hasConceptScore W2318994932C124490489 @default.
• W2318994932 hasConceptScore W2318994932C126322002 @default.
• W2318994932 hasConceptScore W2318994932C134018914 @default.
• W2318994932 hasConceptScore W2318994932C170493617 @default.
• W2318994932 hasConceptScore W2318994932C2776541429 @default.
• W2318994932 hasConceptScore W2318994932C2776940978 @default.
• W2318994932 hasConceptScore W2318994932C2777621572 @default.
• W2318994932 hasConceptScore W2318994932C2779740938 @default.
• W2318994932 hasConceptScore W2318994932C2780106736 @default.
• W2318994932 hasConceptScore W2318994932C2781208988 @default.
• W2318994932 hasConceptScore W2318994932C519063684 @default.
• W2318994932 hasConceptScore W2318994932C71924100 @default.
• W2318994932 hasConceptScore W2318994932C74373430 @default.
• W2318994932 hasLocation W23189949321 @default.
• W2318994932 hasOpenAccess W2318994932 @default.
• W2318994932 hasPrimaryLocation W23189949321 @default.
• W2318994932 hasRelatedWork W1991632481 @default.
• W2318994932 hasRelatedWork W1999545086 @default.
• W2318994932 hasRelatedWork W2053499167 @default.
• W2318994932 hasRelatedWork W2064236298 @default.
• W2318994932 hasRelatedWork W2071103727 @default.
• W2318994932 hasRelatedWork W2107762597 @default.
• W2318994932 hasRelatedWork W2248345023 @default.
• W2318994932 hasRelatedWork W2318994932 @default.
• W2318994932 hasRelatedWork W2405065647 @default.
• W2318994932 hasRelatedWork W2577600309 @default.
• W2318994932 hasVolume "2" @default.
• W2318994932 isParatext "false" @default.
• W2318994932 isRetracted "false" @default.
• W2318994932 magId "2318994932" @default.
• W2318994932 workType "article" @default.